VENTANA ALK (D5F3) CDX ASSAY

Immunohistochemistry Assay, Antibody, Anaplastic Lymphoma Kinase

FDA Premarket Approval P140025

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the ventana alk (d5f3) cdx assay. This device is indicated for the following:ventana alk (d5f3) cdx assay is intended for the qualitative detection of the anaplastic lymphoma kinase (alk) protein in formalin-fixed, paraffin-embedded (ffpe) non-small cell lung carcinoma (nsclc) tissue stained with a benchmark xt automated staining instrument. It is indicated as an aid in identifying patients eligible for treatment with xalkori® (crizotinib).

DeviceVENTANA ALK (D5F3) CDX ASSAY
Classification NameImmunohistochemistry Assay, Antibody, Anaplastic Lymphoma Kinase
Generic NameImmunohistochemistry Assay, Antibody, Anaplastic Lymphoma Kinase
ApplicantVENTANA MEDICAL SYSTEMS, INC.
Date Received2014-11-14
Decision Date2015-06-12
Notice Date2015-07-10
PMAP140025
SupplementS
Product CodePKW
Docket Number15M-2219
Advisory CommitteePathology
Expedited ReviewNo
Combination Product Yes
Applicant Address VENTANA MEDICAL SYSTEMS, INC. 1910 East Innovation Park Dr. tucson, AZ 85755
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P140025Original Filing
S018 2022-07-12 30-day Notice
S017 2022-02-16 Special (immediate Track)
S016 2022-01-28 135 Review Track For 30-day Notice
S015 2021-02-22 Real-time Process
S014 2020-11-16 Normal 180 Day Track
S013 2020-08-26 Real-time Process
S012 2020-01-13 Real-time Process
S011 2019-08-22 Real-time Process
S010 2018-11-09 30-day Notice
S009 2018-06-18 Real-time Process
S008
S007 2017-07-17 30-day Notice
S006 2017-06-07 Normal 180 Day Track
S005 2016-12-28 Normal 180 Day Track
S004 2016-11-15 Normal 180 Day Track
S003 2016-03-22 Normal 180 Day Track
S002 2015-12-10 135 Review Track For 30-day Notice
S001 2015-08-26 30-day Notice

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.